Vascular Neurology

Latest News

Cardiovascular Drugs Do Not Impact COVID-19 Outcomes

Cardiovascular drugs do not affect COVID-19 outcomes, according to a review published online.

Study Explores Central Retinal Artery Occlusion Imaging Options

Acute stroke treatment has been transformed by multimodal imaging tools, the report shows.

Omega-3 Fatty Acids Tied to Better Cardiovascular Outcomes

Omega-3 fatty acids (FAs) are associated with lower cardiovascular mortality and improved cardiovascular outcomes.

ADA: Efpeglenatide Lowers Risk for Adverse CV Events in Type 2 Diabetes

For patients with type 2 diabetes and a history of CVD or current kidney disease, the risk for adverse cardiovascular events is lower with efpeglenatide.

Hundreds of US Adults With Reversible Cerebral Vasoconstriction Syndrome Hospitalized Every Year

The incidence of reversible cerebral vasoconstriction syndrome (RCVS) cases leading to hospitalizations is approximately 3 per million adults every year, and the incidence is more than 3 times higher in women than men, according to study results published in Neurology. The diagnostic criteria for RCVS in patients with severe acute headaches with or without additional…

Signs of Intracranial Hypertension on MRI Not Commonly Associated With Papilledema

The study also says chronic intracranial hypertension likely does not require systematic lumbar puncture, unless papilledema is present.

Elective Revascularization Decreases Cardiac Mortality of CAD Patients

The researchers reviewed all trials comparing elective coronary revascularization plus medical therapy vs medical therapy alone for managing stable patients with coronary artery disease to determine the value of these approaches.

Predicting Neurologic Recovery After Cardiac Arrest With MRI Data

Study researchers aimed to test the prognostic value of brain MRI in addition to clinical and electrophysiologic data in patients after cardiac arrest.

ACC: Fish Oil Does Not Improve Outcomes for Those at High CV Risk

High levels of eicosapentaenoic acid, an omega-3 (ω-3) fatty acid, are no benefit to patients at high risk for cardiovascular events.

Venous Thromboembolic Event Rates Increased With ChAdOx1-S Vaccine

The rates of venous thromboembolic events, including cerebral venous thrombosis, are increased among recipients of the Oxford-AstraZeneca vaccine ChAdOx1-S.